Association between a functional polymorphism (-1195T>C) in the IGFBP5 promoter and head and neck cancer risk

Head and Neck

Volumn 33, Issue 5, 2011, Pages 650-660

  Niu, Jiangong ^a   Huang, Yu Jing ^a   Wei, Sheng ^a   Liu, Zhensheng ^a   Wang, Li E ^a   Chang, Shine ^a   Chamberlain, Robert M ^a   El Naggar, Adel K ^a   Sturgis, Erich M ^a   Wei, Qingyi ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

association; head and neck cancer; IGFBP5; polymorphism; TNM stage

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 5; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; CANCER RISK; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; GENOTYPE; HEAD AND NECK CARCINOMA; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; SQUAMOUS CELL CARCINOMA; SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK; WART VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; YOUNG ADULT;

EID: 79954487891     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21514     Document Type: Article

References (34)

1. Sturgis EM, Cinciripini PM,. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer 2007; 110: 1429-1435. (Pubitemid 47463055)
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
3. Hashibe M, Brennan P, Chuang SC, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2009; 18: 541-550.
4. Hsu TC, Spitz MR, Schantz SP,. Mutagen sensitivity: a biological marker of cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1991; 1: 83-89.
5. Ho T, Wei Q, Sturgis EM,. Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck. Head Neck 2007; 29: 682-699. (Pubitemid 47168239)
6. Neumann AS, Sturgis EM, Wei Q,. Nucleotide excision repair as a marker for susceptibility to tobacco-related cancers: a review of molecular epidemiological studies. Mol Carcinog 2005; 42: 65-92.
7. Valentinis B, Baserga R,. IGF-I receptor signalling in transformation and differentiation. Mol Pathol 2001; 54: 133-137. (Pubitemid 32539602)
8. Kim JJ, Accili D,. Signalling through IGF-I and insulin receptors: where is the specificity? Growth Horm IGF Res 2002; 12: 84-90. (Pubitemid 37337006)
9. Hwa V, Oh Y, Rosenfeld RG,. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 1999; 20: 761-787. (Pubitemid 30648894)
10. Firth SM, Baxter RC,. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23: 824-854. (Pubitemid 35454590)
11. Mohan S, Baylink DJ,. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol 2002; 175: 19-31. (Pubitemid 35276583)
12. Beattie J, Allan GJ, Lochrie JD, Flint DJ,. Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J 2006; 395: 1-19.
13. Lochrie JD, Phillips K, Tonner E, et al. Insulin-like growth factor binding protein (IGFBP)-5 is upregulated during both differentiation and apoptosis in primary cultures of mouse mammary epithelial cells. J Cell Physiol 2006; 207: 471-479.
14. Chang KW, Hung PS, Lin IY, et al. Curcumin upregulates insulin-like growth factor binding protein-5 (IGFBP-5) and C/EBPalpha during oral cancer suppression. Int J Cancer 2010; 127: 9-20.
15. Hung PS, Kao SY, Shih YH, et al. Insulin-like growth factor binding protein-5 (IGFBP-5) suppresses the tumourigenesis of head and neck squamous cell carcinoma. J Pathol 2008; 214: 368-376.
16. Lin SC, Wang CP, Chen YM, et al. Regulation of IGFBP-5 expression during tumourigenesis and differentiation of oral keratinocytes. J Pathol 2002; 198: 317-325.
17. Patel SG, Shah JP,. TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin 2005; 55: 242-258; quiz 261-262, 264. (Pubitemid 41271230)
18. Andrews NC, Faller DV,. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 1991; 19: 2499.
19. Hong Y, Miao X, Zhang X, et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 2005; 65: 9582-9587. (Pubitemid 41508029)
20. Garner CP, Ding YC, John EM, et al. Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent. Hum Genet 2008; 123: 247-255.
21. Rho SB, Dong SM, Kang S, et al. Insulin-like growth factor-binding protein-5 (IGFBP-5) acts as a tumor suppressor by inhibiting angiogenesis. Carcinogenesis 2008; 29: 2106-2111.
22. Nakamura M, Miyamoto S, Maeda H, et al. Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability. Biochem Biophys Res Commun 2005; 333: 1011-1016. (Pubitemid 40854257)
23. Hyde C, Hollier B, Anderson A, Harkin D, Upton Z,. Insulin-like growth factors (IGF) and IGF-binding proteins bound to vitronectin enhance keratinocyte protein synthesis and migration. J Invest Dermatol 2004; 122: 1198-1206. (Pubitemid 38651095)
24. Wang H, Arun BK, Wang H, et al. IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J 2008; 14: 261-267. (Pubitemid 351678058)
25. Hou XJ, Zhang YZ, Liu X, Meng LH, Qiao YB,. Expressions of IGFBP-5, cFLIP in cervical intraepithelial neoplasia, cervical carcinoma and their clinical significances: a molecular pathology. J Exp Clin Cancer Res 2009; 28: 70.
26. Hoang CD, D'Cunha J, Kratzke MG, et al. Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 2004; 125: 1843-1852. (Pubitemid 38648420)
27. Curran T, Franza BR Jr,. Fos and Jun: the AP-1 connection. Cell 1988; 55: 395-397. (Pubitemid 18261431)
28. Ozanne BW, Spence HJ, McGarry LC, Hennigan RF,. Transcription factors control invasion: AP-1 the first among equals. Oncogene 2007; 26: 1-10. (Pubitemid 46067326)
29. Zhu X, Ling N, Shimasaki S,. Cloning of the rat insulin-like growth factor binding protein-5 gene and DNA sequence analysis of its promoter region. Biochem Biophys Res Commun 1993; 190: 1045-1052. (Pubitemid 23207870)
30. Yasuoka H, Yamaguchi Y, Feghali-Bostwick CA,. The pro-fibrotic factor IGFBP-5 induces lung fibroblast and mononuclear cell migration. Am J Respir Cell Mol Biol 2009; 41: 179-188.
31. Kiepe D, Ciarmatori S, Hoeflich A, Wolf E, Tönshoff B,. Insulin-like growth factor (IGF)-I stimulates cell proliferation and induces IGF binding protein (IGFBP)-3 and IGFBP-5 gene expression in cultured growth plate chondrocytes via distinct signaling pathways. Endocrinology 2005; 146: 3096-3104. (Pubitemid 41002819)
32. Xin X, Hou YT, Li L, et al. IGF-I increases IGFBP-5 and collagen alpha1(I) mRNAs by the MAPK pathway in rat intestinal smooth muscle cells. Am J Physiol Gastrointest Liver Physiol 2004; 286: G777-783. (Pubitemid 38506809)
33. Johnson SK, Haun RS,. Insulin-like growth factor binding protein-5 influences pancreatic cancer cell growth. World J Gastroenterol 2009; 15: 3355-3366.
34. Hipskind RA, Büscher D, Nordheim A, Baccarini M,. Ras/MAP kinase-dependent and -independent signaling pathways target distinct ternary complex factors. Genes Dev 1994; 8: 1803-1816.